- Home
- CHNR vs PFSA Comparison
CHNR vs PFSA Comparison
Compare CHNR & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHNR | PFSA |
|---|---|---|
| Founded | N/A | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 3.7M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHNR | PFSA |
|---|---|---|
| Price | $3.42 | $2.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.7K | ★ 253.6K |
| Earning Date | 12-31-2025 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 122.22 |
| 52 Week Low | $3.16 | $1.88 |
| 52 Week High | $8.20 | $957.00 |
Technical Indicators
Market Signals| Indicator | CHNR | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 65.89 |
| Support Level | $3.50 | $0.05 |
| Resistance Level | $3.83 | $4.22 |
| Average True Range (ATR) | 0.31 | 0.24 |
| MACD | -0.06 | 0.28 |
| Stochastic Oscillator | 0.00 | 47.04 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About PFSA Profusa Inc.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.